The Food and Drug Administration on Monday approved the oral version of Novo Nordisk’s injectable weight loss drug Wegovy, making it the first GLP-1 pill to be cleared by regulators for obesity and possibly allowing many more Americans to access a highly effective treatment.
The Wegovy pill, whose approval for weight loss was widely anticipated, has also been approved to reduce cardiovascular risks, similar to the injectable version.